NSU Associate Professor Discusses How Supreme Court Nominee Kavanaugh Could Impact Healthcare

On July 16, 2018, Judge Brett Kavanaugh was nominated by President Trump to the Supreme Court, filling in Justice Anthony Kennedy’s seat. Kavanaugh is a conservative judge whose former stances regarding health care policy could impact future healthcare legislation.

Daniel E. Dawes, J.D., associate professor of Complex Health Systems at NSU, spoke how Kavanaugh may support the FDA’s oversight of experimental drugs. In the 2007 case, Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, Kavanaugh said that, “there is no fundamental right ‘deeply rooted in this nation’s history and tradition’ of access to experimental drugs for the terminally ill.” Dawes also mentioned how Kavanaugh may be in favor to government policies regarding pharmaceuticals and how he may vote conservatively in abortion and contraception cases.

Daniel E. Dawes, J.D

The M.B.A. from NSU’s H. Wayne Huizenga College of Business and Entrepreneurship with a Concentration in Complex Health Systems is ideal for those looking to broaden their knowledge of the business of health care, including those in both clinical and non-clinical positions in hospitals, management services organizations, pharmaceutical companies, insurance organizations, and other medical industries.

To read the full article, click on the link below:

Natalie Register